AndroGel

DRUG8 trials

Conditions

Diabetes Mellitus Type 2HypogonadismHypogonadism, MaleMale Breast CancerPainProstate CancerSecondary HypogonadismType 2 Diabetic Male With Hypogonadotrophic Hypogonadism

Phase 2

Effects of Testosterone Replacement on Pain Sensitivity and Pain Perception

CompletedNCT00351819

Boston UniversityHypogonadism, Pain

Start: 2006-04-30End: 2012-11-30Updated: 2017-06-28

Testosterone Replacement in Men With Non-Metastatic Castrate Resistant Prostate Cancer

TerminatedNCT00515112

University of ChicagoProstate Cancer

Start: 2007-07-31End: 2012-08-31Updated: 2014-06-11

Gonadal Dysfunction in Male Long-term Survivors of Malignant Lymphoma; Vitality

CompletedNCT04492553

Lars Møller PedersenHypogonadism

Start: 2021-04-01End: 2022-11-10Updated: 2022-11-29

Phase 3

Study to Evaluate the Safety and Efficacy of Androxal™ Treatment in Men With Secondary Hypogonadism

CompletedNCT00962637

Repros Therapeutics Inc.Secondary Hypogonadism

Start: 2006-03-31End: 2007-05-31Updated: 2010-02-11

Efficacy and Safety of Oral Testosterone Undecanoate in Hypogonadal Men

CompletedNCT03198728

Marius PharmaceuticalsHypogonadism, Male

Start: 2017-07-05End: 2020-05-01Updated: 2023-06-28

Phase 4

Effect of Androgel on Type 2 Diabetic Males With Hypogonadism

CompletedNCT00350701

University at BuffaloDiabetes Mellitus Type 2

Start: 2006-07-31End: 2013-07-31Updated: 2022-02-10

Unknown Phase

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

TerminatedNCT00467987

University at BuffaloType 2 Diabetic Male With Hypogonadotrophic Hypogonadism

Start: 2007-06-01End: 2018-10-11Updated: 2024-02-06

Testosterone & Tamoxifen Trial

TerminatedNCT05156606

University Medical Center GroningenMale Breast Cancer

Start: 2022-11-10End: 2024-07-31Updated: 2024-08-09

Related Papers

A phase III, single-arm, 6-month trial of a wide-dose range oral testosterone undecanoate product

Therapeutic Advances in Urology2024-01-012 citations